24.5 C
New York
Thursday, July 3, 2025

Tag: antigen

newssourcecompanyFORcontentinformation1marketbusiness

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Antigen Security Announces Collaboration with Microsoft to Offer Up to 60% Savings on Cyber Insurance Premiums

FLINT, Mich., June 26, 2025 /PRNewswire/ -- Antigen Security, LLC ("Antigen") today announced a new partner program with Microsoft, affirming Antigen as one of...

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025

BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting...

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

−  Results show delivery of high radiation doses to tumours compared with normal organs.−  Observed normal organ absorbed dosimetry results may allow administration of...

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

−  Results show delivery of high radiation doses to tumours compared with normal organs.−  Observed normal organ absorbed dosimetry results may allow administration of...

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients

As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease. AURORA, Colo.,...

COVID-19 Kits Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges

The Global COVID-19 Kits Market is projected to grow from USD 5.67 billion in 2025 to USD 9.03 billion by 2032, at a CAGR of 6.9%. This market provides essential tools for diagnosing COVID-19 with PCR, antigen, and antibody tests. Rapid innovation, regulatory support, and digital tools enhance market growth. 
The Global COVID-19 Kits Market is projected to grow from USD 5.67 billion in 2025 to USD 9.03 billion by 2032, at a CAGR of 6.9%. This market provides essential tools for diagnosing COVID-19 with PCR, antigen, and antibody tests. Rapid innovation, regulatory support, and digital tools enhance market growth.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAntigen

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers